Protective Step Training in Parkinson's Disease

July 18, 2022 updated by: Arizona State University

Protective Step Training in People With Parkinson's Disease and Postural Disturbances

The primary purpose of this project is to determine the preliminary effectiveness of protective step training to improve balance and reduce falls in people with Parkinson's disease (PD) and postural disturbances. A secondary purpose is to understand which baseline patient characteristics predict responsiveness to treatment. By informing 1) the effectiveness of a promising rehabilitative intervention, and 2) the selection of the participants that will be most responsive to treatment, these data may enhance clinicians' ability to treat balance disturbances in people with PD. Importantly, protective step training, described in this proposal, can be quickly deployed in the clinic at minimal cost. Therefore, if shown to be effective via this and subsequent trials, this approach can be easily integrated into care, immediately impacting a large number of people with PD.

Study Overview

Status

Completed

Conditions

Detailed Description

This project contains 3 aims: Aims 1 and 2 address the primary goal of this project: Determining the effectiveness of protective step training. Aim 1 will test whether perturbation training can improve protective stepping in people with PD with postural dysfunction. Aim 2 will test whether improvements are retained over 2 months and generalize to untrained perturbation tasks (which may be important for real world situations). Importantly, investigators will also gather exploratory data regarding the effect of perturbation training on falls. Aim 3 addresses the secondary goal of this project: Determining for whom protective step training is most beneficial. Aim 3 will relate behavioral factors and neuroimaging outcomes to the magnitude of improvement in protective stepping. All aims will be tested in people with PD who have postural disturbances.

To complete these aims, participants will undergo 12 visits to the laboratory over the course of about 5 months. These will include 6 "training visits" over the course of 2 weeks, surrounded by 6 "assessment" visits before and after the training. During assessment visits, investigators will assess the ability to step quickly in response to a loss of balance (e.g. a slip), as well as thinking assessments and, if eligible, investigators will complete an MRI. During training visits, investigators will train the ability to step quickly in response to a slip.

In this study, participants will serve as their own controls. As such, there is no randomization to multiple groups.

Study Type

Interventional

Enrollment (Actual)

35

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Arizona
      • Phoenix, Arizona, United States, 85004
        • Arizona State University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years to 90 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Neurologist diagnosed PD
  • Postural Instability / Gait Dysfunction (PIGD)
  • Ability to stand unaided for 5 minutes

Exclusion Criteria:

  • non-PD related neurological pathology
  • orthopedic impairments affecting balance

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Multi-baseline Step Training
Participants will be assessed before and after a 2-week baseline period, and again before and after a 2 week "protective step training period. Participants will also be assessed 2 months later at a follow-up visit.
Participants will undergo 6, 1 hour visits (over the course of 2 weeks) where they will be exposed to repeated slips on a treadmill.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stepping performance, measured as Margin of Stability (MOS)
Time Frame: Change across baseline period (2 weeks), compared to change across intervention period (2 weeks)
MOS: Distance between the extrapolated center of mass and base of support at first foot contact after the slip
Change across baseline period (2 weeks), compared to change across intervention period (2 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stepping performance, measured as First Step Length
Time Frame: Change across baseline period (2 weeks), compared to change across intervention period (2 weeks)
Step Length: Length of the first step after the slip
Change across baseline period (2 weeks), compared to change across intervention period (2 weeks)
Stepping performance, measured as First Step Latency
Time Frame: Change across baseline period (2 weeks), compared to change across intervention period (2 weeks)
Step Latency: Time taken to lift the foot off the ground after the slip start
Change across baseline period (2 weeks), compared to change across intervention period (2 weeks)
Cognition, measured as the total score on the "SCales for Outcomes in PArkinson's disease-COGnition" (SCOPA-COG)
Time Frame: Baseline
SCOPA-COG: This scale characterizes cognitive capacity of several domains, and was developed specifically for people with PD. Range: 0-43 (higher score reflects better cognitive capacity). Subscales/domains are calculated, and the *total* score is calculated as the sum of each subscale.
Baseline
Structural brain connectivity between the cortex (supplementary motor area), and basal ganglia (striatum)
Time Frame: Baseline
Diffusion Tensor Imaging data (collected via MRI), will be collected and analyzed to characterize the structural connectivity specifically between the cortex and basal ganglia.
Baseline

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Retention of stepping improvement (measured as Margin of Stability; MOS) over 2 months
Time Frame: Change in MOS score from Baseline to Follow-up (10 weeks between collections)
Characterization of whether MOS changes observed over training period are retained at follow-up.
Change in MOS score from Baseline to Follow-up (10 weeks between collections)
Generalization of stepping improvement (measured as Margin of Stability; MOS)
Time Frame: Change in MOS score from Baseline 2 to Post (2 weeks between collections)
Characterize whether training impacts MOS of an untrained reactive stepping task
Change in MOS score from Baseline 2 to Post (2 weeks between collections)
Fall frequency
Time Frame: Change in the number of falls during baseline (2 months) and follow-up (2 months) periods.
Number of falls will be recorded via fall calendar in the 2 month period prior to training (baseline) and the 2 month period following training (post)
Change in the number of falls during baseline (2 months) and follow-up (2 months) periods.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Daniel Peterson, Arizona State University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

June 1, 2019

Primary Completion (ACTUAL)

April 1, 2022

Study Completion (ACTUAL)

June 1, 2022

Study Registration Dates

First Submitted

March 19, 2019

First Submitted That Met QC Criteria

March 28, 2019

First Posted (ACTUAL)

March 29, 2019

Study Record Updates

Last Update Posted (ACTUAL)

July 20, 2022

Last Update Submitted That Met QC Criteria

July 18, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared outside of the primary investigator and backup contact, noted above.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe